Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma

NCT04318730 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT04318730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04318730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma
Lead sponsor
West China Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
October 1, 2020
Completion date
April 1, 2025
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adrenocortical carcinoma